CAMP and asthma: One novel aspect of the present in vivo study is that mCRAMP was intranasally administered together with OVA during the challenge stage of the asthmatic model, mimicking the increased airway expression of LL-37 induced by acute bacterial/viral infections during asthma exacerbations.